Maxalt Max (Rizatriptan Benzoate)

Rizatriptan selectively stimulates 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This causes vasoconstriction of dilated intracranial arteries and blocks the release of inflammatory neuropeptides, interrupting the migraine pain pathway.

The prescribed dose of Maxalt Max is determined by the treating physician based on the patient’s clinical condition, previous response to therapy, and any relevant contraindications. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

Safety data for rizatriptan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Maxalt Max, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maxalt Max (rizatriptan) belongs to the Triptan class, which is generally more specific for migraine relief than non‑specific analgesics such as NSAIDs. Compared with other triptans, rizatriptan has a rapid onset of action and a relatively short half‑life, making it suitable for early treatment of attacks.

Store Maxalt Max tablets at room temperature, below 25 °C. Keep them in the original blister pack or container, protect from moisture, direct sunlight and excessive heat to maintain product stability.

Maxalt Max is taken orally as a tablet. The patient should swallow the tablet whole with water, preferably at the first sign of a migraine attack. If needed, a second dose may be taken after at least two hours, following the prescriber’s guidance.

Serious risks include coronary vasospasm, myocardial infarction, and serotonin syndrome, especially when combined with other serotonergic drugs. Patients should be monitored for chest pain, tightness, or any signs of allergic reaction, and seek immediate medical attention if such symptoms occur.

Maxalt Max should be avoided in patients with a history of coronary artery disease, uncontrolled hypertension, recent myocardial infarction, severe hepatic impairment, or known hypersensitivity to rizatriptan or any excipients. It is also contraindicated when used with MAO inhibitors or other triptans.